LianBio Announces Completion of Strategic Review
February 13, 2024 07:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to...
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
August 28, 2023 16:05 ET
|
LianBio
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023Data from the trial published simultaneously in JAMA CardiologyMavacamten demonstrated improvement in Valsalva LVOT peak...
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET
|
LianBio
Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic...
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
August 03, 2023 16:05 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
July 17, 2023 06:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
June 26, 2023 08:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian...
LianBio to Participate in Upcoming Investor Conferences
June 01, 2023 16:15 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 16:15 ET
|
LianBio
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointChina National Medical Products Administration (NMPA) accepted...
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
May 11, 2023 07:00 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
联拓生物公布Mavacamten在用于治疗中国患者的EXPLORER-CN III期临床试验中获得积极顶线结果
April 26, 2023 08:00 ET
|
LianBio
Mavacamten在治疗中国有症状的梗阻性肥厚型心肌病患者的研究中达到了主要终点Mavacamten显示出与之前研究结果相一致的安全性特征未来如获批，mavacamten将成为中国首个被批准用于治疗梗阻性肥厚型心肌病的心肌肌球蛋白抑制剂联拓生物将于美国东部时间5月1日（星期一）上午8点/中国时间晚8点召开线上直播会议，就EXPLORER-CN试验的顶线数据及mavacamten在中国的市场机会与...